New patient trials surrounding this compound, specifically the high-dose formulation branded as ZPHC, reveal a significant impact on weight decrease and associated chronic conditions . Experts believe that this innovative compound, affecting both GLP-1 and GIP systems, could provide a substantial improvement in the management of excess weight and